Showing papers by "Christian Junghanss published in 2012"
University of Texas MD Anderson Cancer Center1, University of California, San Francisco2, University of Bologna3, Bombay Hospital, Indore4, Hospital General de México5, Catholic University of Korea6, University of Rostock7, Medical University of Łódź8, University Medical Center Groningen9, Bristol-Myers Squibb10
TL;DR: Primary data showed superior efficacy for dasatinib compared with imatinib after 12 months, including significantly higher rates of complete cytogenetic response (CCyR), confirmed CCyR (primary end point), and major molecular response (MMR).
546 citations
TL;DR: The therapeutic strategy could become a new standard of care after autologous stem-cell transplantation; however, prophylactic platelet transfusion should remain the standard for patients with acute myeloid leukaemia.
273 citations
TL;DR: Azacitidine is active and well tolerated in elderly patients with newly diagnosed AML, and lower marrow blasts on day 15 of cycle 1, irrespective of pretreatment count, predicted subsequent response.
Abstract: The safety and efficacy of azacitidine (5-day schedule) were assessed in a multicenter study in 40 patients (median age 72 years) with acute myeloid leukemia (AML) medically unfit for (n = 20) or resistant to chemotherapy (n = 20) from April to October 2008. Median marrow blasts were 42%. After a median follow-up of 13 months, response (complete remission [CR]/partial remission [PR]/hematologic improvement [HI]) was 50% and 10% in newly diagnosed and relapsed/refractory patients, respectively (p = 0.008). Median time-to-response was 2.5 months with a median duration of 5.9 months. Median survival was not reached for responders versus 3.8 months for 15 (38%) patients with stable disease (p < 0.045). High-risk cytogenetics was associated with inferior survival (p = 0.05). Lower marrow blasts on day 15 of cycle 1, irrespective of pretreatment count, predicted subsequent response (p = 0.01). Azacitidine is active and well tolerated in elderly patients with newly diagnosed AML.
102 citations
TL;DR: It is demonstrated that non-immune HMGB1-non-secreting cells of epithelial origin derived from mammary non-neoplastic tissue can be induced to release HMGB 1 by single cytokine application, indicating that tumor and surrounding tissue can been stimulated by tumor present inflammatory and necrotic cytokines to releaseHMGB1 acting as neo-vascularizing factor thus promoting tumor growth.
25 citations
TL;DR: Immunosuppression consisting of RAD001 and CsA is well tolerated but not as efficient as with other established immunosuppressants in a canine nonmyeloablative HSCT regimen, and does not support the application of RAD002/CsA as standard practice in this setting.
13 citations
TL;DR: It is highlighted that application of Denileukin Diftitox resulted in a depletion of T(reg) followed by an increase of immune response in vitro, which could not be confirmed in vivo even if the immune system was stimulated by vaccinations.
6 citations
TL;DR: This report escribes complex clinical and paraclinical findings demonstrating the difficulties in diagnosing a T cell lymphoma with cerebral nvolvement.